Why EworldwireTM

Get Specialized Delivery : Deliver your press release via the highest regarded and respected PR newswire service. All media targeting services - from writing, to video, podcast and photo - are provided in-house by the ONLY BUSINESS WIRE TO OFFER THESE SERVICES COMPLETELY IN-HOUSE. ARCHIVE YOUR PRESS RELEASE INDEFINITELY - NOT JUST 7 OR 30 DAYS- and benefit from the long-term long tail impact of your news release when the public is searching online, with no hidden costs.

Login

logo

NeuroHealing Pharmaceuticals Inc.
Internet:
info@neurohealing.com
http://www.neurohealing.com

Company Information :
NeuroHealing Pharmaceuticals Inc.
50 Undine Road
Suite #1
Newton, MA 02135
USA
Ph. 617.331.4111
Fx. 617.777.1267

Media Contacts:
Daniel Katzman
President
617.331.4111
info@NeuroHealing.com

Oct. 6-7: NeuroHealing Pharmaceuticals To Present At Drug Repositioning Summit In Boston

Media Advisory

NEWTON, Mass./EWORLDWIRE/Sep. 24, 2008 --- NeuroHealing Pharmaceuticals, a private clinical stage company developing innovative products for individuals with chronic brain injuries and neurodegenerative diseases, will present a talk entitled, "There's Still Low Hanging Fruit: Three Repositioned Drugs in Clinical Testing for Brain Injury Patients," at the third annual Drug Repositioning Summit: Finding New Routes to Success. The conference will be held on October 6-7, 2008 in Boston, Mass., organized by Cambridge Healthtech Institute. Neal M. Farber, Ph.D., CEO of NeuroHealing, will present case studies on the company's three repositioned products in development for new indications - each with early evidence of clinical efficacy, extensive human safety data and based on novel formulation and/or drug delivery strategies.

Information about the conference may be obtained from 'http://www.healthtech.com/rjv/overview.aspx?c=525'.

About NeuroHealing Pharmaceuticals

NeuroHealing Pharmaceuticals, Inc. is a clinical stage company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system.

Clinical stage programs include:

. NH001 (phase II), a dopaminergic agent reformulated to be administered via a continuous sc pump to accelerate the recovery and improve the cognitive and functional outcome of patients from a coma following a traumatic brain injury
. NH004 (phase II), an anticholinergic drug reformulated in an intra-oral, muco-adhesive, slow dissolving thin strip designed for patient convenience to control sialorrhea (drooling); and NH02D, a stereoisomer of a marketed, novel mechanism drug reformulated for sublingual delivery

Contact
NeuroHealing Pharmaceuticals, Inc.
Daniel Katzman, President
617.331.4111
'http://www.NeuroHealing.com'
info@NeuroHealing.com

HTML:   http://www.eworldwire.com/pressreleases/19007
PDF:   http://www.eworldwire.com/pdf/19007.pdf
MOBILE:    http://e4mobile.com/view_release.php?id=19007
ONLINE NEWSROOM:   http://www.eworldwire.com/newsroom/305366.htm
NEWSROOM RSS FEED:   http://newsroom.eworldwire.com/xml/newsrooms/305366.xml
LOGO:   http://www.eworldwire.com/newsroom/305366.htm

CONTACT:
Daniel Katzman
NeuroHealing Pharmaceuticals
PHONE. 6173314111
http://www.NeuroHealing.com

SOURCE: NeuroHealing Pharmaceuticals


(Top)